Evolut™ PRO+ system Transcatheter Aortic Valve Replacement (TAVI)
The next generation Evolut™ PRO+ transcatheter aortic valve system provides industry-leading hemodynamics — allowing your patients to return to activity faster.1,2,3
Download brochure
Overview
Meet the Evolut™ PRO+ system
ADVANCED
SEALING
LOW DELIVERY
PROFILE
HEMODYNAMIC
PERFORMANCE
Product details
Treat more
patients
Leadership
in valve design
Control
during deployment
Expect more optimize PRO study
8.8%
Permanent pacemaker rate at 30 days3
0%
moderate/severe PVL at discharge3
0 deaths
and disabling strokes at 30 days3
8.1% mm Hg
gradient at discharge
Experts corner
Resources
Manuals and technical guides
Access instructions for use and other technical manuals in the Medtronic Manual Library. Search by the product name (e.g., Evolut) or model number.
Evolut™ PRO+ platform resources
*
Broadest annulus range based on CT derived diameters.
1
Bleiziffer S, Eichinger WB, Hettich I, et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after bioprosthesis aortic valve replacement. Heart. May 2008;94(5):637-641.
2
van Slooten YJ, van Melle JP, Freling HG, et al. Aortic valve prosthesis-patient mismatch and exercise capacity in adult patients with congenital heart disease. Heart. January 2016;102(2):107-113.
3
Pibarot P, Dumesnil JG, Jobin J, Cartier P, Honos G, Durand LG. Hemodynamic and physical performance during maximal exercise in patients with an aortic bioprosthetic valve: comparison of stentless versus stented bioprostheses. J Am Coll Cardiol. November 1, 1999;34(5):1609-1617.
4
Up to 80% deployment. The valve can be partially or fully recaptured up to three times prior to the point of no recapture. Third attempt must be a complete recapture and retrieval from patient.